Merck Serono in discovery deal to plump up immuno-oncology pipeline
This article was originally published in Scrip
Executive Summary
Merck Serono, the biopharmaceutical arm of Merck of Germany, has signed an agreement with German biotech MorphoSys to discover and develop therapeutic antibodies against undisclosed immune checkpoints with the aim of developing new immune-oncology compounds.